-
1
-
-
84908178824
-
The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010
-
Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001–2010. Am J Infect Control. 2014;42(10):1028–1032.
-
(2014)
Am J Infect Control
, vol.42
, Issue.10
, pp. 1028-1032
-
-
Reveles, K.R.1
Lee, G.C.2
Boyd, N.K.3
Frei, C.R.4
-
2
-
-
0000795948
-
Intestinal flora in new-born infants: With a description of a new pathogenic anaerobe, Bacillus difficilis
-
Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.
-
(1935)
Am J Dis Child
, vol.49
, pp. 390-402
-
-
Hall, I.C.1
O’Toole, E.2
-
3
-
-
0028271412
-
-
Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis. 1994;18(Suppl 4):S265–S272.
-
(1994)
Clostridium Difficile
, vol.18
, Issue.4
, pp. S265-S272
-
-
Bartlett, J.G.1
-
4
-
-
56849106496
-
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing
-
Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280.
-
(2008)
Plos Biol
, vol.6
, Issue.11
-
-
Dethlefsen, L.1
Huse, S.2
Sogin, M.L.3
Relman, D.A.4
-
5
-
-
79952756960
-
Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation
-
Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(Suppl 1): 4554–4561.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 4554-4561
-
-
Dethlefsen, L.1
Relman, D.A.2
-
6
-
-
78049494788
-
Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome
-
Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836.
-
(2010)
Plos One
, vol.5
, Issue.3
-
-
Jakobsson, H.E.1
Jernberg, C.2
Ersson, A.F.3
Sjolund-Karlsson, M.4
Jansson, J.K.5
Engstrand, L.6
-
7
-
-
77954581650
-
Etal. The changing epidemiology of Clostridium difficile infections
-
Freeman J, Bauer MP, Baines SD, etal. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23(3): 529–549.
-
(2010)
Clin Microbiol Rev
, vol.23
, Issue.3
, pp. 529-549
-
-
Freeman, J.1
Bauer, M.P.2
Baines, S.D.3
-
8
-
-
84897824639
-
Community-acquired Clostridium difficile infection: An increasing public health threat
-
Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.
-
(2014)
Infect Drug Resist
, vol.7
, pp. 63-72
-
-
Gupta, A.1
Khanna, S.2
-
9
-
-
84868017013
-
. Burden of gastrointestinal disease in the United States: 2012 update
-
Peery AF, Dellon ES, Lund J, etal. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5): e1171–e1173.
-
(2012)
Gastroenterology
, vol.143
, Issue.5
, pp. e1171-e1173
-
-
Peery, A.F.1
Dellon, E.S.2
Lund, J.3
-
10
-
-
84860348952
-
Clinical and economic burden of Clostridium difficile infection in Europe: A systematic review of healthcare-facility-acquired infection
-
Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1–14.
-
(2012)
J Hosp Infect
, vol.81
, Issue.1
, pp. 1-14
-
-
Wiegand, P.N.1
Nathwani, D.2
Wilcox, M.H.3
Stephens, J.4
Shelbaya, A.5
Haider, S.6
-
11
-
-
84880691277
-
. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011
-
Chitnis AS, Holzbauer SM, Belflower RM, etal. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–1367.
-
(2013)
JAMA Intern Med
, vol.173
, Issue.14
, pp. 1359-1367
-
-
Chitnis, A.S.1
Holzbauer, S.M.2
Belflower, R.M.3
-
12
-
-
84936107665
-
The importance of considering different healthcare settings when estimating the burden of Clostridium difficile
-
Kuntz JL, Polgreen PM. The importance of considering different healthcare settings when estimating the burden of Clostridium difficile. Clin Infect Dis. 2014;60(6):831–836.
-
(2014)
Clin Infect Dis
, vol.60
, Issue.6
, pp. 831-836
-
-
Kuntz, J.L.1
Polgreen, P.M.2
-
13
-
-
84922693344
-
. Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)
-
Davies KA, Longshaw CM, Davis GL, etal. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014; 14(12):1208–1219.
-
(2014)
Lancet Infect Dis
, vol.14
, Issue.12
, pp. 1208-1219
-
-
Davies, K.A.1
Longshaw, C.M.2
Davis, G.L.3
-
14
-
-
84941922680
-
-
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed December 26, 2014.
-
-
-
-
15
-
-
0023296842
-
Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation
-
Clasener HA, Vollaard EJ, van Saene HK. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis. 1987;9(2):295–328.
-
(1987)
Rev Infect Dis
, vol.9
, Issue.2
, pp. 295-328
-
-
Clasener, H.A.1
Vollaard, E.J.2
Van Saene, H.K.3
-
17
-
-
84922906286
-
New perspectives in Clostridium difficile disease pathogenesis
-
Monaghan TM. New perspectives in Clostridium difficile disease pathogenesis. Infect Dis Clin North Am. 2015;29(1):1–11.
-
(2015)
Infect Dis Clin North Am
, vol.29
, Issue.1
, pp. 1-11
-
-
Monaghan, T.M.1
-
18
-
-
84856959278
-
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics
-
Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742–748.
-
(2012)
J Antimicrob Chemother
, vol.67
, Issue.3
, pp. 742-748
-
-
Hensgens, M.P.1
Goorhuis, A.2
Dekkers, O.M.3
Kuijper, E.J.4
-
19
-
-
39449122789
-
Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients
-
Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol. 2008;29(1):44–50.
-
(2008)
Infect Control Hosp Epidemiol
, vol.29
, Issue.1
, pp. 44-50
-
-
Baxter, R.1
Ray, G.T.2
Fireman, B.H.3
-
20
-
-
0031675366
-
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam
-
Settle CD, Wilcox MH, Fawley WN, Corrado OJ, Hawkey PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther. 1998;12(12):1217–1223.
-
(1998)
Aliment Pharmacol Ther
, vol.12
, Issue.12
, pp. 1217-1223
-
-
Settle, C.D.1
Wilcox, M.H.2
Fawley, W.N.3
Corrado, O.J.4
Hawkey, P.M.5
-
21
-
-
84866675037
-
. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England
-
Wilcox MH, Shetty N, Fawley WN, etal. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056–1063.
-
(2012)
Clin Infect Dis
, vol.55
, Issue.8
, pp. 1056-1063
-
-
Wilcox, M.H.1
Shetty, N.2
Fawley, W.N.3
-
22
-
-
3543110833
-
. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea
-
Wilcox MH, Freeman J, Fawley W, etal. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004;54(1): 168–172.
-
(2004)
J Antimicrob Chemother
, vol.54
, Issue.1
, pp. 168-172
-
-
Wilcox, M.H.1
Freeman, J.2
Fawley, W.3
-
23
-
-
79958827058
-
Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection
-
Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48.
-
(2011)
Clin Infect Dis
, vol.53
, Issue.1
, pp. 42-48
-
-
Stevens, V.1
Dumyati, G.2
Fine, L.S.3
Fisher, S.G.4
Van Wijngaarden, E.5
-
24
-
-
33846153776
-
Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
-
Dellit TH, Owens RC, McGowan JE Jr, Infectious Diseases Society of America; Society for Healthcare Epidemiology of America, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
-
(2007)
Clin Infect Dis
, vol.44
, Issue.2
, pp. 159-177
-
-
Dellit, T.H.1
Owens, R.C.2
McGowan, J.E.3
-
25
-
-
33747065605
-
. Impact of diversity of antibiotic use on the development of antimicrobial resistance
-
Sandiumenge A, Diaz E, Rodriguez A, etal. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother. 2006;57(6):1197–1204.
-
(2006)
J Antimicrob Chemother
, vol.57
, Issue.6
, pp. 1197-1204
-
-
Sandiumenge, A.1
Diaz, E.2
Rodriguez, A.3
-
27
-
-
84859086665
-
. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients
-
Alonso CD, Treadway SB, Hanna DB, etal. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053–1063.
-
(2012)
Clin Infect Dis
, vol.54
, Issue.8
, pp. 1053-1063
-
-
Alonso, C.D.1
Treadway, S.B.2
Hanna, D.B.3
-
28
-
-
84879879355
-
. Clostridium difficile infection among hematopoietic stem cell transplant recipients: Beyond colitis
-
Alonso CD, Marr KA. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis. 2013;26(4):326–331.
-
(2013)
Curr Opin Infect Dis
, vol.26
, Issue.4
, pp. 326-331
-
-
Alonso, C.D.1
Marr, K.A.2
-
29
-
-
84875930188
-
. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients
-
Neofytos D, Kobayashi K, Alonso CD, etal. Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients. Trans Infect Dis. 2013;15(2):134–141.
-
(2013)
Trans Infect Dis
, vol.15
, Issue.2
, pp. 134-141
-
-
Neofytos, D.1
Kobayashi, K.2
Alonso, C.D.3
-
30
-
-
84887259304
-
European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection
-
Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
-
(2014)
Clin Microbiol Infect
, vol.20
, pp. 1-26
-
-
Debast, S.B.1
Bauer, M.P.2
Kuijper, E.J.3
-
31
-
-
84905057299
-
Polymer Alternative for CDI Treatment (PACT) investigators, etal. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials
-
Johnson S, Louie TJ, Gerding DN, Polymer Alternative for CDI Treatment (PACT) investigators, etal. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345–354.
-
(2014)
Clin Infect Dis
, vol.59
, Issue.3
, pp. 345-354
-
-
Johnson, S.1
Louie, T.J.2
Gerding, D.N.3
-
32
-
-
84856718514
-
Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection
-
Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis. 2012;54(4):568–574.
-
(2012)
Clin Infect Dis
, vol.54
, Issue.4
, pp. 568-574
-
-
Venugopal, A.A.1
Johnson, S.2
-
33
-
-
84880509237
-
Advances in the treatment of Clostridium difficile with fidaxomicin: A narrow spectrum antibiotic
-
Sears P, Ichikawa Y, Ruiz N, Gorbach S. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Ann N Y Acad Sci. 2013;1291:33–41.
-
(2013)
Ann N Y Acad Sci
, vol.1291
, pp. 33-41
-
-
Sears, P.1
Ichikawa, Y.2
Ruiz, N.3
Gorbach, S.4
-
34
-
-
79551527297
-
, OPT-80-003 Clinical Study Group, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection
-
Louie TJ, Miller MA, Mullane KM, OPT-80-003 Clinical Study Group, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422–431.
-
(2011)
N Engl J Med
, vol.364
, Issue.5
, pp. 422-431
-
-
Louie, T.J.1
Miller, M.A.2
Mullane, K.M.3
-
35
-
-
84859007390
-
, OPT-80-004 Clinical Study Group, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial
-
Cornely OA, Crook DW, Esposito R, OPT-80-004 Clinical Study Group, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet. 2012;12(4):281–289.
-
(2012)
Lancet
, vol.12
, Issue.4
, pp. 281-289
-
-
Cornely, O.A.1
Crook, D.W.2
Esposito, R.3
-
36
-
-
84863686440
-
Study 003/004 Teams, etal. Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials
-
Crook DW, Walker AS, Kean Y, Study 003/004 Teams, etal. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis. 2012;55(Suppl 2):S93–S103.
-
(2012)
Clin Infect Dis
, vol.55
, Issue.2
, pp. S93-S103
-
-
Crook, D.W.1
Walker, A.S.2
Kean, Y.3
-
37
-
-
84941881983
-
-
Wilcox MH, Hawkey PM, Patel B, Planche T, Stone S. Updated guidance on the management and treatment of Clostridium difficile infection; 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf. 2013 Accessed January 17, 2015.
-
-
-
Wilcox, M.H.1
Hawkey, P.M.2
Patel, B.3
Planche, T.4
Stone, S.5
-
38
-
-
84875952150
-
-
Surawicz CM, Brandt LJ, Binion DG, etal. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498. [quiz 499].
-
-
-
Surawicz, C.M.1
Brandt, L.J.2
Binion, D.G.3
-
39
-
-
84939574142
-
Investigational new treatments for Clostridium difficile infection
-
Ivarsson ME, Leroux J, Castagner B. Investigational new treatments for Clostridium difficile infection. Drug Discov Today. 2015;20: 602–608.
-
(2015)
Drug Discov Today
, vol.20
, pp. 602-608
-
-
Ivarsson, M.E.1
Leroux, J.2
Castagner, B.3
-
40
-
-
67049107861
-
. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin
-
Tarkkanen AM, Heinonen T, Jõgi R, etal. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin. Antimicrob Agents Chemother. 2009;53(6):2455–2462.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.6
, pp. 2455-2462
-
-
Tarkkanen, A.M.1
Heinonen, T.2
Jõgi, R.3
-
41
-
-
84923255561
-
Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections
-
Bhansali SG, Mullane K, Ting LS, Leeds J, Dabovic K, Praestgaard J. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2014;59:19.
-
(2014)
Antimicrob Agents Chemother
, vol.59
, pp. 19
-
-
Bhansali, S.G.1
Mullane, K.2
Ting, L.S.3
Leeds, J.4
Dabovic, K.5
Praestgaard, J.6
-
42
-
-
39349107697
-
. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea
-
Chang JY, Antonopoulos DA, Kalra A, etal. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435–438.
-
(2008)
J Infect Dis
, vol.197
, Issue.3
, pp. 435-438
-
-
Chang, J.Y.1
Antonopoulos, D.A.2
Kalra, A.3
-
43
-
-
74849098405
-
. Treatment with monoclonal antibodies against Clostridium difficile toxins
-
Lowy I, Molrine DC, Leav BA, etal. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197–205.
-
(2010)
N Engl J Med
, vol.362
, Issue.3
, pp. 197-205
-
-
Lowy, I.1
Molrine, D.C.2
Leav, B.A.3
-
44
-
-
77951015898
-
-
Safdar A. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(15):1444–1445. [author reply 1445–1446].
-
-
-
Safdar, A.1
-
45
-
-
84884681207
-
Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection
-
Gens KD, Elshaboury RH, Holt JS. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Prac. 2013;26(5):498–505.
-
(2013)
J Pharm Prac
, vol.26
, Issue.5
, pp. 498-505
-
-
Gens, K.D.1
Elshaboury, R.H.2
Holt, J.S.3
-
46
-
-
84922540799
-
Immune-based treatment and prevention of Clostridium difficile infection
-
Zhao S, Ghose-Paul C, Zhang K, Tzipori S, Sun X. Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother. 2014;10(12):3522–3530.
-
(2014)
Hum Vaccin Immunother
, vol.10
, Issue.12
, pp. 3522-3530
-
-
Zhao, S.1
Ghose-Paul, C.2
Zhang, K.3
Tzipori, S.4
Sun, X.5
-
47
-
-
78649807947
-
Management of Clostridium difficile infection: Thinking inside and outside the box
-
Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis. 2010;51(11): 1306–1313.
-
(2010)
Clin Infect Dis
, vol.51
, Issue.11
, pp. 1306-1313
-
-
Gerding, D.N.1
Johnson, S.2
|